10,740
-0.19%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Whanin Pharm Co
Its shares trade on KRX under the ticker 016580.KS. It has been listed since 3 July 1996. In the fiscal year to 31 December 2025, it reported revenue of ₩255.21bn and net income of ₩13.60bn. At that date it held total assets of ₩478.89bn and shareholders' equity of ₩421.01bn.
Whan In Pharmaceutical Co., Ltd. engages in the manufacture and sale of medical supplies. The company is headquartered in Seoul, Seoul. is a Korea-based company specialized in the manufacturing of pharmaceutical products. The Company’s products consist of antidepressants, antipsychotics, anxiolytics, hypnotics, antiepileptics, attention-deficit/hyperactivity disorder (ADHD) agents, nootropics, antiparkinson drugs, anti-dementia drugs, gastrointestinal drugs, cardiovascular drugs, immunostimulating agents, antibiotics, multi-vitamins, respiratory drugs, dermatologic drugs, antivirals, anti-diabetic agents and others. The firm also involves in the real estate rental business.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Jul 1996
- Employees
- 663
- Website
- whanin.com ↗
Leadership
Pay as last reported
- Won Beom LeePresident, Co-Chief Executive Officer, Director, since 2010
- Gye Gwan LeeVice Chairman, since 2012
- Byeong Yeon YooVice President, Director, since 2006
- Byeong Rak AhnManaging Director
- Jong Su KimManaging Director
- Yun Bae KimManaging Director
- Seung Won LeeAssistant Managing Director
- Dong Su LeeAssistant Managing Director
- Seung Sik LeeAssistant Managing Director
- Gwang Su HaNon-Executive Independent Director
- Sang Won HwangNon-Executive Independent Director
- Gi Ok JangNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Whanin Pharm Co Ltd manufactures antidepressants and antipsychotics in Seoul, Korea.
- The company employs 663 full-time staff specializing in pharmaceutical manufacturing.
- Whanin Pharm offers a wide range of drugs including cardiovascular and anti-diabetic agents.
Weaknesses
- Whanin Pharm's real estate rental business is a minor segment of its operations.
- The company has no listed international expansion plans beyond Korea.
- Whanin Pharm's product range lacks biologics and innovative cancer treatments.
Opportunities
- The Korean pharmaceutical market shows growth in cardiovascular and anti-diabetic drugs.
- Whanin Pharm can expand its real estate rental business in Seoul.
- Increasing demand for mental health drugs in Asia presents a new market segment.
Threats
- Competition from global pharmaceutical firms in the antidepressant market.
- Regulatory changes in Korea could affect drug manufacturing approvals.
- Rising costs of raw materials may impact production expenses.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.